Related references
Note: Only part of the references are listed.Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A. Goy et al.
ANNALS OF ONCOLOGY (2009)
Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels
Daniele Baiz et al.
BIOCHIMIE (2009)
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial
Owen A. O'Connor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
John Gerecitano et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma
Yoko Tabe et al.
CLINICAL CANCER RESEARCH (2009)
β-TrCP-Mediated Ubiquitination and Degradation of PHLPP1 Are Negatively Regulated by Akt
Xin Li et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study
Oliver Weigert et al.
LEUKEMIA & LYMPHOMA (2009)
Bortezomib: A novel chemotherapeutic agent for hematologic malignancies
Kyle N. Utecht et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2008)
Proteasomal inhibition stabilizes topoisomerase IIα protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide)
Lauren M. Congdon et al.
BIOCHEMICAL PHARMACOLOGY (2008)
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
Luca Paoluzzi et al.
BLOOD (2008)
Targeting the eIF4F translation initiation complex for cancer therapy
Bruce W. Konicek et al.
CELL CYCLE (2008)
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage - Independent p53 phosphorylation in mantle cell lymphoma
Richard J. Jones et al.
CLINICAL CANCER RESEARCH (2008)
Proteasome inhibitors in cancer therapy: Lessons from the first decade
Robert Z. Orlowski et al.
CLINICAL CANCER RESEARCH (2008)
Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma
Delphine Rolland et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma
Ulrike Heider et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Eukaryotic translation initiation factor 4E-Induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors
Ola Larsson et al.
CANCER RESEARCH (2007)
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak
Patricia Perez-Galan et al.
BLOOD (2007)
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma
O. Weigert et al.
LEUKEMIA (2007)
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma
T. Haritunians et al.
LEUKEMIA (2007)
The cellular origin of mantle cell lymphoma
Francesco Bertoni et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma
Paul G. Richardson et al.
CURRENT OPINION IN ONCOLOGY (2006)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines
Jordi Camps et al.
LEUKEMIA RESEARCH (2006)
Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity
SJ Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Update on the molecular biology of mantle cell lymphoma
F Bertoni et al.
HEMATOLOGICAL ONCOLOGY (2006)
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
P Perez-Galan et al.
BLOOD (2006)
p21Cip1 and p27Kip1 induce distinct cell cycle effects and differentiation programs in myeloid leukemia cells
MJ Muñoz-Alonso et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells
M Duechler et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Proteasome inhibition as a novel therapeutic target in human cancer
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The development of proteasome inhibitors as anticancer drugs
J Adams
CANCER CELL (2004)
Caspase activation inhibits proteasome, function during apoptosis
XM Sun et al.
MOLECULAR CELL (2004)
The role of the unfolded protein response in tumour development: Friend or foe?
YJ Ma et al.
NATURE REVIEWS CANCER (2004)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
N Mitsiades et al.
BLOOD (2003)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
A Rosenwald et al.
CANCER CELL (2003)
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
RZ Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival
Y Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Delayed mammary gland involution in MMTV-AKT1 transgenic mice
S Ackler et al.
ONCOGENE (2002)
Share Paper
